Solid lipid nanoparticles (SLNs) are submicron colloidal carriers formed from physiological lipids that remain solid at ambient and body temperatures. They combine the biocompatibility and ...

Lipid nanoparticle delivery systems encompass a range of colloidal carriers—including liposomes, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs)—designed to encapsulate and ...

LNPs are solid or semi-solid particles at room temperature. They are composed of a lipid core stabilized by surfactants or other agents. This lipid core provides a hydrophobic environment ideal for ...

The earliest iteration of LNPs was the development of liposomes in the 1960s, with the first liposome-based drug product, Doxil, receiving FDA approval in 1995. In the early 1990s, a second generation ...

Encapsulating an active substance in a liposome or lipid nanoparticle can minimize cytotoxicity and increase blood circulation by bypassing the immune system. Several techniques can improve a drug's ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...

Lipid-based nanoparticles (LNPs) are becoming an essential platform in pharmaceutical research and manufacturing. They’re used to improve the delivery of mRNA, enhance the absorption of poorly ...

A study from FAU has shown that lipid nanoparticles restructure their membrane significantly after being absorbed into a cell and ending up in an acidic environment. Vaccines and other medicines are ...

A delivery system that uses lipid nanoparticles to sneak proteins into cells can accomplish the same feat by smuggling ...

Messenger ribonucleic acid (mRNA)-based therapeutics and the potential of mRNA as a treatment for various conditions has been researched for decades. A key challenge remains finding a delivery system ...

Researchers have developed a new lipid nanoparticle design that directs mRNA to the pancreas by exploiting the organ’s own filtration barrier, a strategy that sidesteps the liver-trapping problem that ...

Researchers at the Icahn School of Medicine at Mount Sinai say they have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a ...